Compare AVTX & ANGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVTX | ANGX |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Movies/Entertainment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 710.1M | 743.3M |
| IPO Year | 2015 | 2021 |
| Metric | AVTX | ANGX |
|---|---|---|
| Price | $7.48 | $3.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 5 |
| Target Price | ★ $44.08 | $8.20 |
| AVG Volume (30 Days) | 1.0M | ★ 1.4M |
| Earning Date | 11-05-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.07 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $27,813,137.00 | ★ $321,558,306.00 |
| Revenue This Year | N/A | $59.48 |
| Revenue Next Year | N/A | $27.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 2312.27 | 233.16 |
| 52 Week Low | $11.21 | $2.05 |
| 52 Week High | $24.27 | $7.00 |
| Indicator | AVTX | ANGX |
|---|---|---|
| Relative Strength Index (RSI) | 18.40 | 32.45 |
| Support Level | N/A | $3.00 |
| Resistance Level | $20.54 | $4.56 |
| Average True Range (ATR) | 0.97 | 0.21 |
| MACD | -0.26 | -0.05 |
| Stochastic Oscillator | 8.65 | 17.53 |
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
Angel Studios Inc is an entertainment company known for crowd-funded films and television projects. It enables creators to share projects and engage audiences directly. The platform allows fans to invest in and promote productions, fostering a community-driven approach to content creation.